Cancer

DELFI Diagnostics to Present Early Detection and Advanced Cancer Monitoring Technology Updates at AACR Annual Meeting

Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research event BALTIMORE and PALO…

8 months ago

DELFI Diagnostics to Present Early Detection and Advanced Cancer Monitoring Technology Updates at AACR Annual Meeting

Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research event BALTIMORE and PALO…

8 months ago

Invitation to presentation of RaySearch’s interim report for the first quarter of 2025

STOCKHOLM, April 25, 2025 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report…

8 months ago

Invitation to presentation of RaySearch’s interim report for the first quarter of 2025

STOCKHOLM, April 25, 2025 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report…

8 months ago

Odense University Hospital selects RayStation

STOCKHOLM, April 25, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that Odense University Hospital (OUH), which is part of…

8 months ago

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential…

8 months ago

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential…

8 months ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus…

8 months ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus…

8 months ago

Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025

PARAMUS, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with…

8 months ago